Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07604272 · ClinicalTrials.gov registry record · Phase 1
Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males
A Phase 1 study, sponsored by Northwestern University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT07604272 is a Phase 1 study that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 30 participants.
The verdict
NCT07604272, a Phase 1 study, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a prospective, single-center, three-arm Phase 1 safety and feasibility trial evaluating anti-estrogen therapy in men age 50 years and older with symptomatic unilateral inguinal hernias. Participants will be randomized to receive fulvestrant 250 mg intramuscularly, fulvestrant 500 mg intramuscularly, or letrozole 5 mg orally for 6 months. The study will evaluate safety, tolerability, feasibility, hormone changes, hernia size, patient-reported outcomes, bone density, and imaging-based hernia classification.
Interventions
- DRUG Fulvestrant
- DRUG Anastrazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2028-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07604272
The ClinicalTrials.gov registry entry for NCT07604272 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fulvestrant is the first listed.
NCT07604272 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07604272 about?
NCT07604272 is a clinical study titled "Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males". This is a prospective, single-center, three-arm Phase 1 safety and feasibility trial evaluating anti-estrogen therapy in men age 50 years and older with symptomatic unilateral inguinal hernias. Participants will be randomized to receive fulvestrant 250 mg intramuscularly, fulvestrant 500 mg intramus...
What is the current status of trial NCT07604272?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2026-07-01. Estimated completion is 2028-06.
What interventions are being tested in trial NCT07604272?
The interventions under investigation include: Fulvestrant (DRUG), Anastrazole (DRUG).
Who is sponsoring clinical trial NCT07604272?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.